De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Eli Lilly Toekomstige groei

Future criteriumcontroles 5/6

Eli Lilly zal naar verwachting groeien in winst en omzet met respectievelijk 28.5% en 17.2% per jaar. De winst per aandeel zal naar verwachting groeien met 28% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 58.7% zijn.

Belangrijke informatie

28.5%

Groei van de winst

28.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.8%
Inkomstengroei	17.2%
Toekomstig rendement op eigen vermogen	58.7%
Dekking van analisten	Good
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Recent updates

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Sep 30

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Sep 20

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

Jul 25

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Jul 16

Wall Street Lunch: Merger Monday In All Its Glory

Jul 08

5 Reasons Eli Lilly Just Keeps Rising

Jun 30

Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)

Jun 24

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

Jun 17

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

Jun 11

These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well

Jun 10

Eli Lilly's Growth And Challenges: A Cautious Buy

Jun 01

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

May 26

Eli Lilly: Bloated Stock

May 01

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Apr 22

Winst- en omzetgroeiprognoses

NYSE:LLY - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	68,484	24,547	17,938	21,915	23
12/31/2025	57,472	19,149	12,234	18,021	27
12/31/2024	46,247	13,958	8,382	13,802	24
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,374	5,713	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	1,711	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei LLY ( 28.5% per jaar) ligt boven de spaarquote ( 2.5% ).

Winst versus markt: De winst van LLY ( 28.5% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).

Hoge groeiwinsten: De winst van LLY zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van LLY ( 17.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van LLY ( 17.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen LLY zal naar verwachting over 3 jaar zeer hoog zijn ( 58.7 %).

Eli Lilly Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.4% to US$989

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Consensus EPS estimates increase by 11%

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Recent updates

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Eli Lilly: Tirzepatide's Winning Streak Continues

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Price target increased by 7.4% to US$989

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Upcoming dividend of US$1.30 per share

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Wall Street Lunch: Merger Monday In All Its Glory

Eli Lilly and Company(NYSE:LLY) dropped from Russell 1000 Growth-Defensive Index

5 Reasons Eli Lilly Just Keeps Rising

First quarter dividend of US$1.30 announced

Eli Lilly and Company Declares Dividend for the Third Quarter of 2024, Payable on September 10, 2024

Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)

Eli Lilly and Company Announces Detailed Results from the Surmount-OSA Phase 3 Clinical Trials Evaluating Tirzepatide Injection

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval

These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well

Eli Lilly and Company Announces Resignation of Anat Ashkenazi as Chief Financial Officer, Effective July 2024

Insider notifies of intention to sell stock

Eli Lilly and Company Appoints Melissa Seymour as Executive Vice President of Global Quality and Member of the Executive Committee, Effective July 22, 2024

Eli Lilly and Company Announces Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Eli Lilly's Growth And Challenges: A Cautious Buy

Eli Lilly: Addressing Supply Challenges Should Accelerate Growth

Eli Lilly and Company Announces Positive Topline Results from the Qwint-2 and Qwint-4 Phase 3 Clinical Trials Evaluating Once-Week Dosing

Eli Lilly and Company Announces Retirement of Alonzo Weems, Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer, Effective December 31, 2024

First quarter dividend of US$1.30 announced

Eli Lilly and Company Declares Dividend for the Second Quarter of 2024, Payable on June 10, 2024

Consensus EPS estimates increase by 11%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Eli Lilly: Bloated Stock

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance for the Year 2024

What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S

Eli Lilly and Company to Report Q1, 2024 Results on Apr 30, 2024

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven